Aerospace and Defense
Automotive
Consumer and Retail
Energy
Financial Services
Healthcare
Insurance
Life sciences
Manufacturing
Public Sector
Technology, Media and Telecommunications
Travel and Transportation
AGIG's Customer Service Transformation
Agentic AI in Insurance
Addressing Technical Debt with DXC Assure Platform
The Hogan API Microservices solution
Build & Innovate
Manage & Optimize
Protect & Scale
AI & Data
DXC IoT & Digital Twin Services
Strategize and accelerate your AI agenda
Explore our tailored options to navigate change
Enhance operational effectiveness, maintain compliance and foster customer trust
Customer Stories
Knowledge Base
AI
Closing the AI execution gap
About DXC
Awards & Recognition
Careers
Partners
Events
Environmental, Social, Governance
Investor Relations
Newsroom
Leadership
Legal & Compliance
DXC leads in the age of AI
Partnership with Manchester United
Partnership with Scuderia Ferrari
DXC Insights | November 3, 2025
Antimicrobial resistance (AMR) is a major global health challenge, making infections harder to treat and putting lives at risk. The overuse and misuse of antibiotics are key contributors to this problem, with studies showing that up to 50% of antibiotics prescribed in hospitals may be unnecessary or inappropriate. Recognizing the need for action, Singapore General Hospital (SGH) teamed up with DXC Technology and Synapxe to create AI-driven solutions that transform how antibiotics are prescribed. The program followed DXC’s Xponential approach, starting with focused MVPs to validate clinical impact and building in observability and governance so recommendations are traceable and auditable as use scales.
At the heart of this collaboration is the “Augmented Intelligence in Infectious Diseases (AI2D)” system. AI2D analyzes patient-specific data, like x-rays, vital signs, symptoms and infection trends, to guide doctors in making smarter decisions about antibiotic prescription. Initially focused on pneumonia and urinary tract infections (UTIs), the system helps reduce unnecessary prescriptions while ensuring patients get the right treatment promptly.
DXC and SGH partnered to build an AI model that helps antimicrobial stewardship program (ASP) teams quickly and accurately evaluate antibiotic use. Using data from patients treated with seven broad-spectrum intravenous antibiotics for UTIs, the model applies advanced clinical reasoning to identify potential misuse cases. This AI solution has improved ASP team efficiency by enabling real-time insights into each patient’s condition and recommending the most suitable treatment approach.
SGH faced a dual challenge: ensuring patients receive timely and accurate antibiotic treatments to prevent complications, while minimizing unnecessary antibiotic use to fight AMR. Doctors often struggle to balance these priorities due to limited real-time information.
For instance, SGH’s ASP teams conducted around 12,000 audits of broad-spectrum antibiotic use in 2018, but manual reviews covered only a fraction of the cases. Expanding audit coverage and shifting to a proactive approach for stewardship became essential.
“Well-intended doctors are constantly balancing the risks and benefits of antibiotic use,” said Dr. Piotr Chlebicki, Senior Consultant at SGH’s Department of Infectious Diseases. “A tool like AI2D is very helpful to guide doctors’ decisions before lab results are available.”
Watch the video to learn more.
AI2D was created to help doctors determine whether antibiotics are necessary and recommend the most appropriate treatments based on clinical data. Designed as an MVP-driven deployment, AI²D includes monitoring and explainability features so clinicians and compliance teams can validate model outputs and monitor performance in real time. The AI2D platform:
With automation, SGH’s ASP team can now focus on complex cases, expand their audit reach, and ensure better antibiotic stewardship. AI2D’s pneumonia model, tested on 2,000 cases in 2023, achieved 90% accuracy in identifying whether antibiotics were necessary. In a review of 2,012 pneumonia treatments, the AI model flagged 624 cases for further review, successfully identifying 87% of intervention cases.
AI2D showcases how AI and automation can transform healthcare by enabling more precise and personalized treatment options. By leveraging advanced technology, DXC Technology helps healthcare organizations like SGH address urgent global challenges, such as AMR, while improving patient care and operational efficiency.
This work follows DXC’s Xponential model and Human+ principles, combining staged MVPs, governance and workforce enablement to move from prototype to trusted, auditable AI in production. The collaboration exemplifies how combining cutting-edge solutions with clinical expertise can lead to meaningful, scalable innovations that transform healthcare practices.